TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer.

Abstract

BACKGROUND:

We investigated the efficacy of TILs and anti-PD1 combination therapy in patients with metastatic cervical cancer with low MSI expression and PDL1-negative.

METHODS:

A total of 80 patients were put on TILs and anti-PD1 combination therapy, and the progression-free survival time (PFS) and overall survival time (OS) were assessed by Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify factors that could predict the prognosis of metastatic cervical cancer in the previously described patients.

RESULTS:

The objective response rate was 25%, whereas the mPFS and mOS were 6.1 and 11.3 months, respectively. The therapeutic efficacy was influenced by the characteristics of TILs, infection with HPV, and development of fever just after the therapy.

CONCLUSION:

Overall, our results show that the combination therapy of TILs and anti-PD1 significantly improves the prognosis of metastatic cervical cancer.

• Authors: Huanhuan Yin, Wei Guo, Xiangling Sun, Ruili Li, Cuihua Feng, Yujie Tan
• Journal: Journal of immunology research (J Immunol Res) Vol. 2020 Pg. 8345235 ( 2020) ISSN: 2314-7156 [Electronic] Egypt
• PMID: 32964058 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 Huanhuan Yin et al.

Chemical References

• B7-H1 Antigen
• Biomarkers, Tumor
• CD274 protein, human
• Cytokines
• Immune Checkpoint Inhibitors
• Programmed Cell Death 1 Receptor

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• B7-H1 Antigen (antagonists & inhibitors)
• Biomarkers, Tumor
• Cytokines (metabolism)
• Cytotoxicity, Immunologic
• Female
• Humans
• Immune Checkpoint Inhibitors (pharmacology, therapeutic use)
• Immunophenotyping
• Kaplan-Meier Estimate
• Lymphocytes, Tumor-Infiltrating (immunology, metabolism, pathology)
• Magnetic Resonance Imaging
• Middle Aged
• Molecular Targeted Therapy
• Prognosis
• Programmed Cell Death 1 Receptor (antagonists & inhibitors)
• Tomography, X-Ray Computed
• Treatment Outcome
• Uterine Cervical Neoplasms (drug therapy, immunology, mortality, pathology)